Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Total Non-Current Liabilities (2018 - 2025)

Historic Total Non-Current Liabilities for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $38.1 million.

  • Exagen's Total Non-Current Liabilities rose 2454.5% to $38.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.1 million, marking a year-over-year increase of 2454.5%. This contributed to the annual value of $35.1 million for FY2024, which is 370.58% up from last year.
  • Exagen's Total Non-Current Liabilities amounted to $38.1 million in Q3 2025, which was up 2454.5% from $33.8 million recorded in Q2 2025.
  • Over the past 5 years, Exagen's Total Non-Current Liabilities peaked at $45.1 million during Q1 2022, and registered a low of $30.5 million during Q1 2024.
  • Its 5-year average for Total Non-Current Liabilities is $36.5 million, with a median of $35.1 million in 2024.
  • Per our database at Business Quant, Exagen's Total Non-Current Liabilities skyrocketed by 2927.58% in 2022 and then crashed by 2823.99% in 2024.
  • Over the past 5 years, Exagen's Total Non-Current Liabilities (Quarter) stood at $37.1 million in 2021, then grew by 15.61% to $42.9 million in 2022, then decreased by 20.98% to $33.9 million in 2023, then rose by 3.71% to $35.1 million in 2024, then rose by 8.26% to $38.1 million in 2025.
  • Its Total Non-Current Liabilities stands at $38.1 million for Q3 2025, versus $33.8 million for Q2 2025 and $33.8 million for Q1 2025.